MOMBA is a selective orthosteric agonist specifically targeting engineered human free fatty acid 2 (hFFA2) receptors, particularly those modified as designer receptors activated by designer drugs (DREADD). It demonstrates selective inactivity towards wild-type hFFA2, hFFA3, and mouse FFA2 receptors. It efficiently inhibits forskolin-induced cAMP levels in cells equipped with the hFFA2-DREADD receptor, exhibiting enhanced potency and comparable efficacy to Sorbic acid. In transgenic mice containing the hFFA2-DREADD gene, MOMBA administration notably slows gut transit and facilitates a concentration-dependent enhancement of GLP-1 secretion from colonic crypts, all while being orally bioavailable.